Stock Events

Stock Events

Lexicon Pharmaceuticals 

€3.53
191
+€0+0% Monday 20:00

Statistics

Day High
3.53
Day Low
3.53
52W High
3.53
52W Low
3.53
Volume
250
Avg. Volume
0
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30JulExpected
Q4 2025
Next
Next
-0.06
-0.05
-0.04
-0.03
Expected EPS
-0.04336786428
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LX31.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap107.83B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for serious diseases, including cystic fibrosis, where there is some overlap in therapeutic areas with Lexicon.
AMGEN
AMGN
Mkt Cap178B
Amgen competes in the biopharmaceutical space, developing drugs that could potentially be in direct competition with Lexicon's pipeline, especially in areas like cardiovascular diseases.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences is involved in the discovery, development, and commercialization of innovative therapeutics in areas overlapping with Lexicon's interests, such as liver disease.
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
Regeneron Pharmaceuticals is known for its innovation in biotechnology, competing with Lexicon in developing drugs for conditions like diabetes and cardiovascular diseases.
Biogen
BIIB
Mkt Cap27.62B
Biogen competes with Lexicon in the biopharmaceutical field, focusing on developing therapies for neurological and neurodegenerative diseases, a potential area of interest for Lexicon.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie operates in similar therapeutic areas as Lexicon, including immunology and oncology, making it a direct competitor in the pharmaceutical market.
Merck
MRK
Mkt Cap277.02B
Merck & Co. is a global healthcare company that competes with Lexicon through its broad range of prescription medicines, vaccines, biologic therapies, and animal health products.
Pfizer
PFE
Mkt Cap149.77B
Pfizer is a direct competitor due to its extensive range of healthcare products that could compete with Lexicon's drug pipeline in various therapeutic areas.
Novartis
NVS
Mkt Cap279.67B
Novartis competes with Lexicon in the pharmaceutical and biotechnology industry, focusing on a wide range of therapeutic areas, including those targeted by Lexicon.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca is a global, science-led biopharmaceutical business that competes with Lexicon in developing innovative medicines in oncology, cardiovascular, renal & metabolism, and respiratory diseases.

About

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Show more...
CEO
Dr. Michael S. Exton Ph.D.
Employees
103
Country
United States
ISIN
US5288723027

Listings

MU
DE
LX31.MU
XNAS
US
LXRX
BOATS
BOATS
LXRX.BOATS

0 Comments

Share your thoughts

FAQ

What is Lexicon Pharmaceuticals stock price today?▼
The current price of LX31.MU is €3.53 EUR — it has increased by +0% in the past 24 hours. Watch Lexicon Pharmaceuticals stock price performance more closely on the chart.
What is Lexicon Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Lexicon Pharmaceuticals stocks are traded under the ticker LX31.MU.
Is Lexicon Pharmaceuticals stock price growing?▼
LX31.MU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Lexicon Pharmaceuticals has showed a +0% increase.
When is the next Lexicon Pharmaceuticals earnings date?▼
Lexicon Pharmaceuticals is going to release the next earnings report on May 07, 2026.
What were Lexicon Pharmaceuticals earnings last quarter?▼
LX31.MU earnings for the last quarter are -0.03 EUR per share, whereas the estimation was -0.06 EUR resulting in a +42.01% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Lexicon Pharmaceuticals have?▼
As of May 06, 2026, the company has 103 employees.
In which sector is Lexicon Pharmaceuticals located?▼
Lexicon Pharmaceuticals operates in the Health & Wellness sector.
When did Lexicon Pharmaceuticals complete a stock split?▼
Lexicon Pharmaceuticals has not had any recent stock splits.
Where is Lexicon Pharmaceuticals headquartered?▼
Lexicon Pharmaceuticals is headquartered in The Woodlands, United States.